Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 43 of the 75 sources its claims cite were checked for support.

Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56

Open access

Abstract

Protein phosphatase 2A (PP2A) is a critical human tumor suppressor. Cancerous inhibitor of PP2A (CIP2A) supports the activity of several critical cancer drivers (Akt, MYC, E2F1) and promotes malignancy in most cancer types via PP2A inhibition. However, the 3D structure of CIP2A has not been solved, and it remains enigmatic how it interacts with PP2A. Here, we show by yeast two-hybrid assays, and subsequent validation experiments, that CIP2A forms homodimers. The homodimerization of CIP2A is confirmed by solving the crystal structure of an N-terminal CIP2A fragment (amino acids 1-560) at 3.0 Å resolution, and by subsequent structure-based mutational analyses of the dimerization interface. We further describe that the CIP2A dimer interacts with the PP2A subunits B56α and B56γ. CIP2A binds to the B56 proteins via a conserved N-terminal region, and dimerization promotes B56 binding. Intriguingly, inhibition of either CIP2A dimerization or B56α/γ expression destabilizes CIP2A, indicating opportunities for controlled degradation. These results provide the first structure-function analysis of the interaction of CIP2A with PP2A/B56 and have direct implications for its targeting in cancer therapy.

Overview

CoChat Summary

## TL;DR

This study reports the first crystal structure of CIP2A and shows that CIP2A forms homodimers via a C-terminal three-helix dimerization interface. It also shows that CIP2A directly binds the PP2A B56a and B56c subunits, and that this binding is promoted by dimerization and contributes to CIP2A protein stability.

## Key findings

  • Yeast two-hybrid screening with full-length CIP2A as bait identified CIP2A itself as a high-confidence interaction partner; selected interaction domain analysis mapped the homodimerization region to amino acids 388–558, with the crystallized fragment CIP2A(1–560) behaving as a dimer.
  • The CIP2A(1–560) crystal structure was solved at 3.0 Å resolution; SEC-MALS gave a molecular mass of 117.2 kDa for CIP2A(1–560), consistent with a dimer (calculated 124.5 kDa).
  • Mutations in the dimer interface reduced dimerization: L533E inhibited dimerization by up to 70%, and R522D caused about 50% inhibition; both mutations also reduced B56a binding.
  • CIP2A directly interacted with PP2A B56 subunits B56a and B56c, with the minimal N-terminal B56-binding region mapped to amino acids 159–245; one mutant, N230E, significantly inhibited B56a binding.
  • Disrupting CIP2A dimerization or depleting B56a/B56c lowered full-length CIP2A protein levels by up to 50% in HEK293T cells, without changing CIP2A mRNA; the L533E effect was also validated in 22RV1 cells and was associated with reduced pAkt Ser473.

## Methods

  • Structural and biochemical study of CIP2A: yeast two-hybrid screening, GST pull-downs, SEC and SEC-MALS, microscale thermophoresis, proximity ligation assay, crystallography, and structure-guided mutagenesis.
  • Sample/cell systems: recombinant human CIP2A(1–560) expressed in E. coli for structural and binding assays; HEK293T, HeLa, and 22RV1 cells for interaction and protein-stability experiments; endogenous CIP2A dimerization assessed in HeLa extracts.
  • Main analyses: crystal structure determination by SeMet SAD at 3.0 Å; quantitative comparison of wild-type vs mutant dimerization and B56 binding; Western blot and RT-qPCR to test effects on protein and mRNA abundance.

## Limitations

  • The authors state that co-crystallization of the CIP2A–B56a complex was “extremely challenging” and remained an ongoing effort, so the exact molecular basis of the interaction was not resolved.
  • They note that although N-terminal and dimerization regions were sufficient for B56 binding, the C-terminal sequences and post-translational modifications of full-length CIP2A might also contribute; this is a limitation of the fragment-based structural work.
  • Evident from the text: the N-terminal half of CIP2A(1–560) had high B factors and was not fully traceable in the structure, so parts of the model are incomplete.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.15252/embr.201642788

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

27 Valid · 2 Not valid · 6 Not checked · 55 Own results and interpretations

51 more claims · 9 with their cited sources checked

Create a free account to see all 90 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 26
  • It may state two separate claims as one. 12
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 47 references

Cited by

See all 99

Metadata

Authors
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., & Westermarck, J.
Affiliations
  • University of Washington (US)
  • Åbo Akademi University (FI)
  • University of Helsinki (FI)
  • Nankai University (CN)
Corresponding author
  • Xu, Wenqing
  • Westermarck, Jukka
Venue
The EMBO Reports
Published
2017-02-07
Volume
18
Issue
3
Pages
437-450
ISSN
  • 1469-221X (ISSN-L)
  • 1469-3178
OpenAlex
W2586089906
Cited by
95
References
47
Citations by year
2026: 1 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 12 · 2019: 13 · 2018: 8 · 2017: 6
FWCI
8.37
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Reports (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Spiral (Imperial College London) (submittedVersion)
Funders
  • Academy of Finland (138963)
  • Cancer Society of Finland
  • Sigrid Juselius Foundation
  • Emil Aaltonen Foundation
  • National Cancer Institute (R21CA201944)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
CIP2A, protein phosphatase 2A, PP2A-B56, protein dimerization, protein-protein interaction, protein stability, protein degradation, tumor suppressor, crystal structure, structure-function analysis, cancer therapy targets
MeSH terms
Autoantigens, Binding Sites, Humans, Membrane Proteins, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Structure-Activity Relationship, Oncogene Proteins, Protein Subunits, Tumor Suppressor Proteins, Protein Interaction Mapping, Intracellular Signaling Peptides and Proteins, Protein Phosphatase 2, Protein Multimerization, Protein Stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. https://app.cochat.ai/papers/10.15252/embr.201642788
The paper
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., & Westermarck, J. (2017). Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. The EMBO Reports. https://doi.org/10.15252/embr.201642788

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.